James Ewing, MD
Medical Oncology · Glendale, AZNPI 1689837601
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 20.2%.
Across 717 payments — averaging $58.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$8K
- AstraZeneca$5K
- Incyte Corporation$5K
- Geron Corporation$4K
- Novartis$2K
- Exelixis Inc.$2K
- plus $16K from 54 others
What the payments were for
- Consulting fees$22,25053%
- Speaking & faculty fees$1,9805%
- Travel & lodging$3,9569%
- Food & beverage$13,78733%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BB-2121$6,067
- CALQUENCE$3,536
- BRUKINSA$2,925
- IMETELSTAT$2,711
- Cabometyx$1,980
- MEKINIST$1,575
- RYTELO$765
- Tepmetko$500
- CT THROMBECTOMY SYSTEM KIT$194
- FLOWTRIEVER CATHETER, S$194
- ZERBAXA$122
- clonoSEQ$122
- BAVENCIO$122
- KEYTRUDA$115
How this compares
$42,005 in reported general payments places this provider in the 85th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 20 | $553,898 |
| ErleadaApalutamide | 34 | $485,314 |
| ImbruvicaIbrutinib | 26 | $397,331 |
| RevlimidLenalidomide | 21 | $372,338 |
| Lenalidomide | 29 | $334,236 |
| PomalystPomalidomide | 14 | $314,231 |
| AlecensaAlectinib Hcl | 11 | $201,054 |
| NubeqaDarolutamide | 15 | $190,552 |
| CalquenceAcalabrutinib Maleate | 12 | $177,267 |
| EliquisApixaban | 108 | $76,503 |
| Abiraterone Acetate | 35 | $43,968 |
| OrgovyxRelugolix | 13 | $34,261 |
| XareltoRivaroxaban | 17 | $18,907 |
| Letrozole | 99 | $2,611 |
| Dexamethasone | 92 | $1,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $2,130 | $553,89820 claims |
| Johnson & JohnsonErleada, Xarelto | $485 | $504,22151 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $255 | $397,33126 claims |
| Bristol Myers SquibbRevlimid | $8,472 | $372,33821 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $854 | $314,23114 claims |
| Genentech USA, Inc.Alecensa | $398 | $201,05411 claims |
| BayerNubeqa | $198 | $190,55215 claims |
| AstraZenecaCalquence | $5,048 | $177,26712 claims |
| PfizerEliquis | $926 | $76,503108 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $25 | $34,26113 claims |
| Lilly USA, LLCOlanzapine | $279 | $18120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Glendale
- Nazish AhmadGlendale$205K
- Justin GoldfarbGlendale$26K
- Martin LangfordGlendale$15K
- Demetrio MamaniGlendale$9K
- Maqbool HalepotaGlendale$4K
- Lamia BoricGlendale$1K
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Daniel von HoffScottsdale$165K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.